Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV. Kumar S, et al. Among authors: rifkin r. Blood. 2012 May 10;119(19):4375-82. doi: 10.1182/blood-2011-11-395749. Epub 2012 Mar 15. Blood. 2012. PMID: 22422823 Free article. Clinical Trial.
Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA. Fonseca R, et al. Among authors: rifkin r. Mayo Clin Proc. 2010 Feb;85(2):197-9; author reply 201-4. doi: 10.4065/mcp.2009.0559. Mayo Clin Proc. 2010. PMID: 20118399 Free PMC article. No abstract available.
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.
Kumar SK, Flinn I, Noga SJ, Hari P, Rifkin R, Callander N, Bhandari M, Wolf JL, Gasparetto C, Krishnan A, Grosman D, Glass J, Sahovic EA, Shi H, Webb IJ, Richardson PG, Rajkumar SV. Kumar SK, et al. Among authors: rifkin r. Leukemia. 2010 Jul;24(7):1350-6. doi: 10.1038/leu.2010.116. Epub 2010 May 27. Leukemia. 2010. PMID: 20508619 Free PMC article. Clinical Trial.
Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.
Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, Essell J, Gaffar Y, Warr T, Neuwirth R, Zhu Y, Elliott J, Esseltine DL, Niculescu L, Reeves J. Niesvizky R, et al. Among authors: rifkin r. J Clin Oncol. 2015 Nov 20;33(33):3921-9. doi: 10.1200/JCO.2014.58.7618. Epub 2015 Jun 8. J Clin Oncol. 2015. PMID: 26056177 Clinical Trial.
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
Berenson JR, Cartmell A, Bessudo A, Lyons RM, Harb W, Tzachanis D, Agajanian R, Boccia R, Coleman M, Moss RA, Rifkin RM, Patel P, Dixon S, Ou Y, Anderl J, Aggarwal S, Berdeja JG. Berenson JR, et al. Among authors: rifkin rm. Blood. 2016 Jun 30;127(26):3360-8. doi: 10.1182/blood-2015-11-683854. Epub 2016 May 12. Blood. 2016. PMID: 27207788 Free PMC article. Clinical Trial.
Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States.
Hari P, Romanus D, Palumbo A, Luptakova K, Rifkin RM, Tran LM, Raju A, Farrelly E, Noga SJ, Blazer M, Chari A. Hari P, et al. Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):152-160. doi: 10.1016/j.clml.2017.12.012. Epub 2018 Jan 5. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29395837 Free article.
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Manda S, Yimer HA, Noga SJ, Girnius S, Yasenchak CA, Charu V, Lyons R, Aiello J, Bogard K, Ferrari RH, Cherepanov D, Demers B, Lu V, Whidden P, Kambhampati S, Birhiray RE, Jhangiani HS, Boccia R, Rifkin RM. Manda S, et al. Among authors: rifkin rm. Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):e910-e925. doi: 10.1016/j.clml.2020.06.024. Epub 2020 Jul 6. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32912820 Free PMC article.
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Facon T, Venner CP, Bahlis NJ, Offner F, White DJ, Karlin L, Benboubker L, Rigaudeau S, Rodon P, Voog E, Yoon SS, Suzuki K, Shibayama H, Zhang X, Twumasi-Ankrah P, Yung G, Rifkin RM, Moreau P, Lonial S, Kumar SK, Richardson PG, Rajkumar SV. Facon T, et al. Blood. 2021 Jul 1;137(26):3616-3628. doi: 10.1182/blood.2020008787. Blood. 2021. PMID: 33763699 Free PMC article. Clinical Trial.
Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect® MM Registry.
Lee HC, Ailawadhi S, Gasparetto CJ, Jagannath S, Rifkin RM, Durie BGM, Narang M, Terebelo HR, Toomey K, Hardin JW, Wagner L, Omel JL, Dhalla M, Liu L, Joshi P, Abonour R; Connect® MM Registry. Lee HC, et al. Among authors: rifkin rm. Blood Cancer J. 2021 Jul 23;11(7):134. doi: 10.1038/s41408-021-00524-1. Blood Cancer J. 2021. PMID: 34301916 Free PMC article. Clinical Trial. No abstract available.
182 results